Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement

Crescita Therapeutics

31/03/2026 12:44

Overview

Canada dermatology firm's Q4 revenue fell yr/yr due to prior-year one-time reimbursement

Gross profit and margin rose, helped by higher-margin skincare sales and lower promotional costs

Company to be acquired by ClinActiv Holdings in all-cash deal at 74% premium, pending approvals

Outlook

Crescita expects acquisition by ClinActiv Holdings to close in Q2 2026

Company says economic uncertainty and softness in skincare market continue to impact operations

Crescita remains focused on operational execution while awaiting acquisition approvals

Result Drivers

PRIOR-YEAR ONE-TIME REIMBURSEMENT - Q4 revenue decline mainly due to $1.62 mln inventory reimbursement in Q4-2024 after amending agreement with largest manufacturing client

SKINCARE AND E-COMMERCE SALES - Higher Q4 skincare revenue, primarily from increased e-commerce sales and incremental revenue from Bacti Control acquisition, partly offset revenue decline

HIGHER OPERATING COSTS - Q4 operating expenses rose mainly due to increased advertising and promotion for digital sales, and higher regulatory, consulting and distribution fees

Company press release: ID:nBwT8Ll4a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
C$5.96 mln
Q4 Adjusted EBITDA
C$70,000
Q4 Gross Margin
54.40%
Q4 Operating Expenses
C$3.62 mln
Q4 Operating Income
-C$381,000
Q4 Pretax Profit
-C$702,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)